Search

Author/Creator D'Haens, G R

11. OP38 Tofacitinib for the treatment of Ulcerative Colitis: An integrated summary of safety data from the global OCTAVE and RIVETING clinical trials. (21st January 2022)

Authors:
Sandborn, W J; D'Haens, G R; Sands, B E; Panaccione, R; Ng, S C; Lawendy, N; Kulisek, N; Guo, X; Mundayat, R; Su, C; Panés, J
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i044
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

12. OP39 Shorter disease duration is associated with better outcomes in patients with moderately to severely active Crohn's Disease treated with risankizumab: Results from the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. (21st January 2022)

Authors:
Peyrin-Biroulet, L; Colombel, J F; Louis, E; Ferrante, M; Motoya, S; Panaccione, R; Torres, J; Ungaro, R C; Kligys, K; Kalabic, J; Zambrano, J; Zhang, Y; D'Haens, G R
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i045
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

14. P268 Development and validation of a novel composite index for the assessment of endoscopic and histologic disease activity in pouchitis: The Atlantic pouchitis index. (30th January 2023)

Authors:
Sedano, R; Ma, C; Hogan, M; Silverberg, M S; Zou, G; D'Haens, G R; Rémillard, J; Mcfarlane, S C; Bojic, B; Bressler, B; Rosenfeld, G; Feakins, R M; Kirsch, R; Marchal, A; Samaan, M A; Panaccione, R; Hart, A; Sands, B E; Travis, S; Feagan, B G
Journal:
Journal of Crohn's and colitis
Issue:
Volume 17(2023)Supplement 1
Page Start:
i416
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

15. P336 Association between the prior duration of remission and efficacy outcomes in patients with Ulcerative Colitis treated with tofacitinib 10 mg twice daily who were in stable remission and either dose-reduced to tofacitinib 5 mg twice daily or remained on 10 mg twice daily: 6-month data from the double-blind, randomised RIVETING study. (27th May 2021)

Authors:
Dubinsky, M C; D'Haens, G R; Sandborn, W J; Ng, S C; Panés, J; Su, C; Lawendy, N; Lazariciu, I; Gardiner, S; Mundayat, R; Kulisek, N; Modesto, I; Torres, J
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S361
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

16. P409 Non-invasive predictors of maintaining remission in patients with moderately to severely active Ulcerative Colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING study. (27th May 2021)

Authors:
D'Haens, G R; Dubinsky, M C; Regueiro, M; Santana, G O; Torres, J; Kulisek, N; Gardiner, S; Mundayat, R; Paulissen, J; Lawendy, N; Su, C; Modesto, I; Sandborn, W J
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S416
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

17. P459 Persistent mesorectal inflammatory activity is associated with complications after proctectomy in Crohn's disease. (16th January 2018)

Authors:
de Groof, E J; van der Meer, J H; Tanis, P J; de Bruyn, J R; van Ruler, O; D'Haens, G R; van den Brink, G R; Bemelman, W A; Wildenberg, M E; Buskens, C J
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S336
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

18. P466 Tofacitinib for the treatment of ulcerative colitis: Up to 5.4 years of safety data from global clinical trials. (25th January 2019)

Authors:
Sandborn, W J; Panés, J; Panaccione, R; D'Haens, G R; Sands, B E; Su, C; Moscariello, M; Jones, T V; Pedersen, R D; Friedman, G S; Lawendy, N; Chan, G
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S344
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

19. P578 Therapy refractory ulcerative colitis patients may benefit from appendectomy: long-term clinical results from a multicentre prospective cohort series. (16th January 2018)

Authors:
Stellingwerf, M E; Sahami, S; Winter, D C; Mulcahy, H E; Doherty, G; Cullen, G; Martin, S; D'Haens, G R; Bemelman, W A; Buskens, C J
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S399
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

20. P588 Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis. (30th January 2023)

Authors:
Jairath, V; Zou, G; Wang, Z; Adsul, S; Colombel, J F; D'Haens, G R; Freire, M; Moran, G W; Peyrin-Biroulet, L; Sandborn, W J; Sebastian, S; Travis, S; Vermeire, S; Radulescu, G; Sigler, J; Mcfarlane, S; Arya, N; Beaton, M; Bossuyt, P; Green, D
Journal:
Journal of Crohn's and colitis
Issue:
Volume 17(2023)Supplement 1
Page Start:
i716
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗